



# Market Announcement

19 June 2024

---

## Botanix Pharmaceuticals Ltd (ASX: BOT) – Trading Halt

### Description

The securities of Botanix Pharmaceuticals Ltd ('BOT') will be placed in trading halt at the request of BOT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 21 June 2024 or when the announcement is released to the market.

### Issued by

ASX Compliance

19 June 2024

Company Announcements  
Australian Securities Exchange  
Level 40  
Central Park  
152 – 158 St Georges Terrace  
PERTH WA 6000

Dear Sir/Madam

**Request for Trading Halt**

Pursuant to ASX Listing Rule 17.1, the Directors of Botanix Pharmaceuticals Limited (ASX: BOT) (“Botanix” or “the Company”) request an immediate trading halt in the securities of the Company pending release of an announcement regarding FDA-approval for Sofdra™.

This trading halt will be in place until release of the Botanix announcement, expected no later than open of trading on Friday, 21 June 2024.

The Company is not aware of any reason why the trading halt should not be granted, nor any other information necessary to inform the market about the trading halt.

By order of the Board



**Susan Park**  
Company Secretary

**For more information, please contact:**

**General enquiries**

Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

**Investor enquiries**

Hannah Howlett  
WE Communications  
P: +61 450 648 064  
[hhowlett@we-worldwide.com](mailto:hhowlett@we-worldwide.com)

**Media enquiries**

Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)